welcome mckesson third quarter fiscal earn conference call please advise today conference record time like turn call investor relation please ahead vice president investor relation thank good afternoon welcome everyone mckesson third quarter fiscal earn call today join chief executive officer chief financial officer lead follow move question answer session today discussion include forward look statement forecast mckesson operation future result please refer cautionary statement today earn release presentation slide available website investor mckesson risk factor section periodic file additional information concern risk factor could cause actual result materially differ forward look statement information financial measure webcast include reconciliation measure result find today earn release presentation slide presentation slide also include summary result quarter update guidance assumption turn chief executive officer thank thank everyone join call today today report third quarter fiscal result another quarter double digit adjust operate profit growth four segment reflect strength fundamental across business focus execution company priority position consistently generate strong financial result despite fluidity continue macroeconomic environment business performance would like quickly remind everyone company priority share strategic transformation diversify healthcare service company center around four enterprise priority believe execution priority critical ability generate long term sustainable growth want reiterate focus commitment first priority people culture diversify portfolio asset operation company touch impact many aspect health healthcare system include patient embed daily operation purpose advance health outcome mission build impact drive organization focus enable change three area improve access healthcare advance health equity protect environment past year employee come together share countless moment impact find involve contribute alone complete volunteer hour support nearly charity proud achieve confident ability build brighter future fact offer greater health outcome part focus culture continue improvement diversity inclusion particular focus hire develop promote call best talent strategy mckesson recently recognize best place work equality ninth year receive honor commitment diversity refreshment include board director welcome independent director board director serve multiple senior leadership role within healthcare industry currently operate partner private equity firm stone prior hold role chief executive officer white health recently hold role executive vice president global chief human resource officer boot alliance lead human capital strategy include merger integration transformation digitization decade healthcare experience prove record lead complicate organization executive leadership role instrumental mckesson excite welcome board additionally announce today elect next independent chairman board effect follow plan transition lead current independent chair want thank year steady leadership invaluable contribution independent chair mckesson board director also want welcome role bring deep leadership expertise share mckesson value culture strategy vision include commitment board diversity look forward leadership stewardship next priority drive sustainable growth core pharmaceutical medical distribution business vast scale distribution network deep expertise global supply chain management critical foundational part long history proud operational excellence ability capture efficiency deliver consistent high quality service customer optimize operate margin build core capability successful expand product category adjacent market like solution government partnership strategy scale asset capability also enable play integral role response pandemic proud serve centralize distributor vaccine ancillary supply government also work closely partner supplier manufacturer navigate complex supply chain system relationship allow continue provide stability supply customer result able manage challenge market third priority streamline business include initiative like split change healthcare strategic intent fully exit region recently announce sale business complete agreement sell country operate reminder remain country enter agreement sell continue work toward close pending divestiture transaction result intentional effort evaluate portfolio strategic alignment believe fully exit region able better focus human financial capital higher growth higher margin area lead naturally next company priority last company priority strategic growth pillar oncology biopharma service past year accelerate growth area build refer ecosystem share investor large grow market significant unmet need opportunity tackle complex problem healthcare system goal bring efficiency benefit stakeholder across ecosystem oncology ecosystem growth strategy center around support large grow diversify oncology network reach physician oncology network treat cancer patient site service oncology network important initiative participation oncology care model five year experimental payment model goal bring cancer base latest result oncology network practice participate program achieve high mark quality metric provide significant save represent approximately fourth provider participate program oncology network demonstrate leadership role transition healthcare value base approach build upon deep reach community oncology space create oncology ecosystem multifaceted service offer interconnect center connectivity oncology technology insight business dedicate help advance cancer research advance patient care recently highlight business investor since launch make great progress transform idea reality sign agreement strategic partner improve patient outcome quality patient care instrumental launch consortium real world research study provide critical information improve patient journey within biopharma ecosystem build differentiate asset capability include business like pharmacy combine prescription solution business share goal improve access adherence affordability medicine customer business biopharma company scale interconnect technology network provide biopharma range commercialization service automate simplify process prior authorization reduce prescription abandonment provide biopharma access patient unique technology capability also generate insight patient need challenge enable greater ability impact patient action better outcome support brand today cover therapeutic area connect major insurance company regional payer unite state reach network deep broad foundation biopharma ecosystem incredibly excite market opportunity bring progress company priority truly outstanding strategy work strong conviction priority north star seek advance marketplace diversify healthcare service company drive long term sustainable growth shareholder turn third quarter result want provide brief update progress make toward broad resolution governmental opioid relate claim date state five territory join propose settlement sign period political subdivision participate state join previously announce propose opioid settlement agreement enter evaluation period deadline decision continue work party bring meaningful relief affect community toward resolution allow focus strategic priority business result please report strong third quarter total company revenue billion adjust earn dilute share ahead expectation result performance underlie business contribution relate item raise adjust earn dilute share guidance previous range third quarter another example nonlinear nature recovery pandemic begin quarter volume utilization trend recover case continue decline across country although expect nonlinear recovery trend emergence spread omicron variant unexpected since closely monitor impact thing learn past year resilience business community regardless trajectory pandemic confident ability adjust adapt support customer patient challenge time turn pharmaceutical segment pharmaceutical segment adjust operate profit growth underpin contribution vaccine distribution increase specialty volume third quarter brand pharmaceutical price track line original expectation consistent experience past several year generic continue benefit success strength source operation scale procurement expertise consistently source product protect integrity safety supply chain also proud role support government pandemic response effort vaccine booster recommendation various group continue expand evolve pharmaceutical business successfully distribute million vaccine administration site across unite state support government international donation mission government extend exist vaccine distribution contract roughly line first quarter fiscal prescription technology solution segment excellent momentum deliver increase segment adjust operate profit third quarter mention earlier offer range commercial service primarily biopharma company quarter growth lead third party logistics service access adherence affordability solution include access patient product segment align focus develop biopharma service ecosystem market focus present many excite opportunity estimate total addressable market around billion good growth potential attractive margin profile please financial performance expect continue drive growth innovation mckesson medical surgical navigate dynamic market grow business surge demand complex supply chain employee work tirelessly secure deliver product play important role fight pandemic dedicate foundation business growth continue invest ensure operational continuity excellence relate international segment continue benefit relate program operation distribute million vaccine administration site select market across international geography look forward fiscal excite progress four company priority since rollout multiyear strategic initiative fiscal focus execution make impact deliver result pandemic continue present unknown certain fiscal another year focus strong execution strategic advancement continue progress toward four priority driver sustainable profit growth strong cash flow shareholder value creation continue focus thing matter customer patient employee shareholder close continue excite future growth prospect meet opportunity diversify healthcare service company unique differentiate asset oncology biopharma service unmatched scale connectivity strategically position grow market lastly conclude want take moment thank dedicate include every employee make mckesson share mission improve healthcare every achieve dedication commitment people opportunity work alongside continue humble deeply grateful thank time afternoon chief financial officer thank good afternoon everyone please today fiscal third quarter result reflect another quarter strong performance across business drive operational execution growth strategy third quarter deliver overall growth compare prior year result across segment include growth prior year exclude relate program start update remain commit fully exit region progress exit activity track today announce transaction sell business management sale mckesson remain share joint venture boot alliance close asset involve transaction contribute approximately billion revenue million adjust operate profit fiscal earn relate joint venture immaterial next pursuant satisfaction customary close condition include receipt regulatory approval anticipate pending divestiture sell mckesson retail distribution business close fourth quarter fiscal transaction sell certain asset group close first half fiscal asset include transaction classify hold sale fiscal guidance include approximately adjust earn dilute share accretion relate pending transaction record within international segment accretion result hold sale account conclude transaction close fiscal currently anticipate approximately adjust earn dilute share accretion relate hold sale account base current estimate close date group transaction remain country enter agreement sell previously discuss anticipate deploy capital offset dilution result divestiture principally share repurchase provide detail third quarter adjust result want point additional item impact result quarter report charge million relate sale retail distribution business account remeasurement asset lower carry amount fair value sell charge largely drive decline pound sterling move adjust result third quarter begin consolidate result find slide discuss investor event manage business long term financial strategic framework focus shareholder value creation financial framework combine three element generate sustainable adjust growth organic growth operate leverage capital allocation framework demonstrate strong third quarter fiscal result additionally leadership support government domestic international vaccine kitting effort continue contribute growth momentum build across business third quarter adjust earn dilute share increase compare prior year result drive strong operational performance across segment relate item include contribution vaccine distribution kitting storage program government test fiscal impairment personal protective equipment relate product lower share count consolidate revenue billion increase prior year primarily drive growth pharmaceutical segment largely higher volume retail national account customer brand pharmaceutical price increase line initial guidance partially offset brand generic conversion adjust gross profit billion quarter increase compare prior year benefit increase contribution strong operational performance previously mention program relate item adjust operate expense quarter increase year year exclude impact hold sale account announce divestiture international segment adjust operate expense increase year year adjust operate profit billion quarter increase compare prior year lead strong operational performance across segment move line interest expense million quarter improvement compare prior year adjust rate quarter wrap consolidate result third quarter dilute weight average share million decrease year year move third quarter segment result find slide start pharmaceutical revenue billion increase year year drive higher volume retail national account customer brand pharmaceutical price increase partially offset brand generic conversion adjust operate profit increase million drive contribution vaccine distribution growth distribution specialty product hospital community commission contribution contract government distribution vaccine provide benefit approximately share quarter line expectation prescription technology solution segment revenue billion increase drive higher volume growth relate biopharma service include third party logistics service increase technology service revenue partially result growth prescription volume adjust operate profit increase million drive growth access adherence solution continue experience growth across broad spectrum higher margin capability offer segment please increase transaction volume relate access adherence solution increase number brand join platform year also experience increase volume logistics service continue recovery prescription volume move medical surgical solution revenue billion increase drive growth primary care business contribution kitting storage distribution ancillary supply vaccine partially offset lower revenue test primary care extend care business compare prior year adjust operate profit increase million drive contribution kitting storage distribution ancillary supply government vaccine program prior year impact inventory impairment charge relate incur third quarter fiscal growth primary care business contribution contract government relate kitting distribution storage ancillary supply vaccine provide benefit approximately share quarter original expectation next address international result revenue quarter billion increase drive customer growth business volume increase pharmaceutical distribution retail business across segment partially offset contribution mckesson wholesale business joint venture boot alliance adjust basis adjust operate profit increase million drive reduction compare prior year depreciation amortization certain asset classify hold sale distribution vaccine test strong distribution result business hold sale account international segment contribute adjust earn quarter move corporate adjust corporate expense million increase year year incur opioid relate litigation expense million third quarter anticipate fiscal opioid relate litigation expense approximately million turn cash position find slide quarter cash balance billion first nine month fiscal year generate free cash flow billion year date make million capital expenditure include investment support strategic pillar oncology biopharma service first nine month fiscal year return billion cash shareholder include billion share repurchase payment million dividend investor event announce board director approve increase billion exist share repurchase program third quarter billion remain share repurchase authorization increase authorization complete sale business remain share joint venture anticipate fiscal fourth quarter closure sale business anticipate execute share repurchase billion fourth quarter result anticipate return approximately billion shareholder share repurchase fiscal strong operate performance combine return capital shareholder reinforce commitment drive shareholder value transition speak outlook remainder fiscal full list fiscal assumption find slide continue anticipate full recovery prescription volume however persistence variant omicron lead nonlinear trajectory pharmaceutical segment anticipate revenue increase adjust operate profit deliver growth prior year continue stable fundamental pharmaceutical business specifically outlook brand pharmaceutical price single digit increase fiscal remain consistent original guidance prior year view generic environment remain competitive stable guidance remain align volume distribution schedule provide government include contribution relate role centralize distributor government vaccine distribution program continue update progress contribution program exclude vaccine distribution segment anticipate approximately adjust operate profit growth reminder investment lead differentiate position oncology continue represent approximate headwind fiscal prescription technology solution segment anticipate revenue growth adjust operate profit growth growth reflect strong momentum business project increase volume across exist biopharma solution customer transition medical surgical outlook assume revenue growth adjust operate profit growth prior year outlook include relate contribution government distribution ancillary supply storage program relate impact test impairment relate product exclude impact item segment anticipate growth prior year additional reminder relate distribution business earn call discuss highly competitive labor market continue persist also outline assumption modest labor relate expense impact ensure support talent strategy continue service continuity second half fiscal year base labor market trend experience third quarter expectation remainder fiscal year continue anticipate approximately adjust operate expense impact distribution business second half year weight slightly higher medical segment finally international segment revenue guidance decline growth compare prior year reminder reflect impact contribution wholesale business joint venture boot alliance third quarter fiscal adjust operate profit guidance reflect growth segment include approximately adjust earn accretion fiscal result hold sale account relate agreement sell certain asset turn consolidate view increase guidance assume revenue growth adjust operate profit growth compare fiscal full year adjust effective rate guidance remain unchanged anticipate corporate expense range million million improvement previous range million million relate focus operate leverage highlight recent investor event turn cash flow capital deployment expect business continue drive strong free cash flow return capital even continue reinvesting support sustainable long term growth strong free cash flow generation provide financial flexibility execute balance capital allocation approach include invest strategic growth pillar oncology biopharma service remain commit return capital shareholder grow dividend share repurchase investment grade credit remain priority underpin financial flexibility fiscal continue anticipate free cash flow approximately billion billion property acquisition capitalize software expense reminder historically generate larger portion cash flow fourth quarter fiscal year work capital metric result cash flow vary quarter quarter impact time could include time plan divestiture activity also anticipate dilute weight share outstanding range million million fiscal include impact anticipate billion fourth quarter share repurchase mention earlier result strong year date performance outlook remainder fiscal year raise narrow previous adjust earn share guidance range previous range update outlook adjust earn dilute share reflect growth compare prior year fiscal adjust earn dilute share guidance also include contribution attributable follow item relate government vaccine distribution relate kitting storage distribution ancillary supply relate test fiscal impairment relate product increase previous range approximately gain loss associate mckesson venture equity investment within corporate segment exclude impact item fiscal guidance fiscal result indicate forecast growth prior year pull together strong performance outlook equate adjust earn dilute share guidance increase compare previous fiscal outlook provide investor adjust earn dilute share increase include follow approximately drive strong underlie business performance operate leverage approximately relate test approximately relate hold sale account reduce opioid litigation expense approximately relate interest expense lower weight average share outstanding spend minute provide initial think fiscal want point provide fiscal guidance time however think would instructive walk item could impact fiscal today first pandemic continue present many unknown continue expect full recovery however likely continue nonlinear fiscal could impact quarterly cadence pharmaceutical medical surgical solution segment contract government serve centralize distributor vaccine assist kitting storage distribution ancillary supply schedule expire outside contract government vaccine distribution anticipate normal customer renewal activity pharmaceutical segment relate test continue anticipate demand closely associate rate case level impact variant moderate prior year level international segment anticipate adjust earn dilute share accretion first half fiscal relate hold sale account base current estimate close date group transaction longer report revenue adjust operate profit hold sale account benefit relate transaction transaction close anticipate opioid litigation expense remain relatively line fiscal guidance complete assessment government entity participation propose settlement final determination regard settlement continue update outcome determination remain opioid litigation expense anticipate investment support growth strategy oncology biopharma service overall continue strength stability underlie fundamental business head fiscal remain optimistic future growth opportunity share detail fiscal outlook fourth quarter earn call close please result fiscal third quarter strong financial outlook mckesson continue deliver strong result successfully execute strategic financial framework continue focus thing matter customer patient shareholder diversify healthcare service company want thank thank employee hard work dedication turn call operator question